Free tool
FAERS Monitor: Gemcitabine Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200795 or its brand name (Gemcitabine Hydrochloride, Gemcitabine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
54,066
Serious
52,517
97% of reports
Hospitalization
21,422
Death reported
10,141
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression4,940
- off label use4,270
- thrombocytopenia3,805
- neutropenia3,364
- anaemia3,158
- malignant neoplasm progression2,987
- drug ineffective2,831
- nausea2,657
- pyrexia2,636
- diarrhoea2,167
- fatigue2,151
- vomiting2,149
- death2,024
- febrile neutropenia1,861
- myelosuppression1,742
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 500 |
| 2005 | 487 |
| 2006 | 551 |
| 2007 | 345 |
| 2008 | 422 |
| 2009 | 596 |
| 2010 | 541 |
| 2011 | 1,057 |
| 2012 | 1,514 |
| 2013 | 1,282 |
| 2014 | 1,550 |
| 2015 | 2,451 |
| 2016 | 2,925 |
| 2017 | 2,848 |
| 2018 | 3,272 |
| 2019 | 3,801 |
| 2020 | 3,649 |
| 2021 | 3,581 |
| 2022 | 4,151 |
| 2023 | 5,189 |
| 2024 | 4,905 |
| 2025 | 4,825 |
| 2026 | 3,624 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,000,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 1,742 | 19.7 | 18.8 | 29,493 |
| disease progressionSignal | 4,940 | 16.9 | 16.5 | 71,225 |
| thrombocytopeniaSignal | 3,805 | 13.7 | 13.2 | 43,374 |
| malignant neoplasm progressionSignal | 2,987 | 11.7 | 11.3 | 28,382 |
| febrile neutropeniaSignal | 1,861 | 11.2 | 10.7 | 16,846 |
| neutropeniaSignal | 3,364 | 9.8 | 9.5 | 26,227 |
| anaemiaSignal | 3,158 | 6.5 | 6.3 | 14,681 |
| pyrexiaSignal | 2,636 | 3.0 | 2.9 | 3,494 |
| off label use | 4,270 | 1.9 | 1.8 | 1,894 |
| vomiting | 2,149 | 1.8 | 1.7 | 750 |
| nausea | 2,657 | 1.3 | 1.3 | 198 |
| diarrhoea | 2,167 | 1.3 | 1.3 | 160 |
| fatigue | 2,151 | 1.1 | 1.0 | 12 |
| death | 2,024 | 0.9 | 0.9 | 17 |
| drug ineffective | 2,831 | 0.8 | 0.8 | 98 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.